Pharsight

Drugs that contain Viltolarsen

1. Viltepso patents expiration

VILTEPSO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10870676 NIPPON SHINYAKU Antisense nucleic acids
Aug, 2031

(7 years from now)

US9079934 NIPPON SHINYAKU Antisense nucleic acids
Aug, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 12, 2025
Orphan Drug Exclusivity (ODE) Aug 12, 2027

NCE-1 date: 2024-08-12

Market Authorisation Date: 12 August, 2020

Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients who have a confirmed mutation of the dmd gene that is amenable to exon 53 skipping

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

VILTEPSO family patents

Family Patents